A detailed history of Janus Henderson Group PLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Janus Henderson Group PLC holds 971,203 shares of NBIX stock, worth $123 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares
971,203
Previous 1,378,513 29.55%
Holding current value
$123 Million
Previous $190 Million 29.67%
% of portfolio
0.07%
Previous 0.11%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$130.86 - $143.19 $53.3 Million - $58.3 Million
-407,310 Reduced 29.55%
971,203 $134 Million
Q1 2024

May 15, 2024

SELL
$130.4 - $143.74 $22.5 Million - $24.8 Million
-172,854 Reduced 11.14%
1,378,513 $190 Million
Q4 2023

Feb 14, 2024

SELL
$106.07 - $132.76 $17.6 Million - $22 Million
-165,687 Reduced 9.65%
1,551,367 $204 Million
Q3 2023

Nov 14, 2023

SELL
$94.02 - $117.1 $18 Million - $22.5 Million
-191,790 Reduced 10.05%
1,717,054 $193 Million
Q2 2023

Aug 14, 2023

SELL
$89.53 - $104.87 $7.67 Million - $8.98 Million
-85,677 Reduced 4.3%
1,908,844 $180 Million
Q1 2023

May 15, 2023

SELL
$94.11 - $123.02 $39.6 Million - $51.8 Million
-421,117 Reduced 17.43%
1,994,521 $202 Million
Q4 2022

Feb 14, 2023

SELL
$106.72 - $127.06 $268 Million - $319 Million
-2,511,196 Reduced 50.97%
2,415,638 $289 Million
Q3 2022

Nov 14, 2022

SELL
$92.03 - $107.81 $26.4 Million - $30.9 Million
-286,900 Reduced 5.5%
4,926,834 $523 Million
Q2 2022

Aug 15, 2022

SELL
$75.79 - $100.07 $83.1 Million - $110 Million
-1,096,029 Reduced 17.37%
5,213,734 $508 Million
Q1 2022

May 16, 2022

SELL
$72.45 - $94.81 $82.3 Million - $108 Million
-1,136,076 Reduced 15.26%
6,309,763 $592 Million
Q4 2021

Feb 14, 2022

SELL
$79.65 - $106.22 $123 Million - $164 Million
-1,540,472 Reduced 17.14%
7,445,839 $634 Million
Q3 2021

Nov 16, 2021

BUY
$86.18 - $99.03 $2.95 Million - $3.39 Million
34,237 Added 0.38%
8,986,311 $862 Million
Q2 2021

Aug 16, 2021

SELL
$89.43 - $102.27 $25 Million - $28.6 Million
-279,215 Reduced 3.02%
8,952,074 $871 Million
Q1 2021

May 17, 2021

BUY
$87.57 - $119.4 $6.14 Million - $8.38 Million
70,148 Added 0.77%
9,231,289 $898 Million
Q4 2020

Feb 16, 2021

BUY
$86.91 - $108.33 $227 Million - $283 Million
2,612,748 Added 39.9%
9,161,141 $878 Million
Q3 2020

Nov 16, 2020

BUY
$96.16 - $135.15 $5.21 Million - $7.33 Million
54,202 Added 0.83%
6,548,393 $630 Million
Q2 2020

Aug 14, 2020

SELL
$85.09 - $130.36 $96.6 Million - $148 Million
-1,135,008 Reduced 14.88%
6,494,191 $792 Million
Q1 2020

May 14, 2020

BUY
$75.11 - $113.76 $19.2 Million - $29.1 Million
255,687 Added 3.47%
7,629,199 $660 Million
Q4 2019

Feb 18, 2020

SELL
$86.8 - $118.57 $98.1 Million - $134 Million
-1,130,024 Reduced 13.29%
7,373,512 $793 Million
Q3 2019

Nov 14, 2019

SELL
$83.82 - $101.5 $71.1 Million - $86.1 Million
-848,704 Reduced 9.07%
8,503,536 $766 Million
Q2 2019

Jul 31, 2019

BUY
$72.24 - $91.27 $39 Million - $49.3 Million
540,279 Added 6.13%
9,352,240 $790 Million
Q1 2019

Apr 30, 2019

BUY
$69.31 - $91.53 $315,152 - $416,186
4,547 Added 0.05%
8,811,961 $776 Million
Q4 2018

Feb 06, 2019

BUY
$68.32 - $124.36 $112 Million - $205 Million
1,644,949 Added 22.97%
8,807,414 $629 Million
Q3 2018

Nov 09, 2018

SELL
$98.88 - $125.85 $25 Million - $31.8 Million
-252,396 Reduced 3.4%
7,162,465 $881 Million
Q2 2018

Aug 10, 2018

SELL
$75.3 - $105.99 $3.7 Million - $5.21 Million
-49,133 Reduced 0.66%
7,414,861 $728 Million
Q1 2018

May 14, 2018

BUY
$75.88 - $92.43 $128 Million - $156 Million
1,691,883 Added 29.31%
7,463,994 $619 Million
Q4 2017

Feb 09, 2018

BUY
$58.53 - $77.59 $15.5 Million - $20.5 Million
264,348 Added 4.8%
5,772,111 $448 Million
Q3 2017

Nov 14, 2017

BUY
$47.97 - $61.28 $6.75 Million - $8.62 Million
140,639 Added 2.62%
5,507,763 $0
Q2 2017

Aug 17, 2017

BUY
N/A
5,367,124
5,367,124 $247 Million

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $12.1B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Janus Henderson Group PLC Portfolio

Follow Janus Henderson Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Janus Henderson Group PLC with notifications on news.